Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Retatrutide is still investigational, while tirzepatide and semaglutide are FDA-approved
GIP receptor activation may further support insulin secretion and metabolic regulation
While GLP-1s are cost-effective for those with diabetes, for those with obesity, these medications are not cost-effective at current prices
In fact, the Food Institute recently highlighted allergen-free and plant-forward options designed to meet these needs
US$ 20.30
US$ 20.28
US$ 28.58
US$ 22.06
